{"id":44291,"date":"2022-05-24T19:01:25","date_gmt":"2022-05-24T17:01:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/"},"modified":"2022-05-24T19:01:25","modified_gmt":"2022-05-24T17:01:25","slug":"ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/","title":{"rendered":"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering"},"content":{"rendered":"
\n

PARIS–(BUSINESS WIRE)–Ikonisys SA <\/b>(Code ISIN: FR00140048X2 \/ Mn\u00e9monique: ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs and the Department of Electronics, Information and Bioengineering (DEIB) of Politecnico di Milano<\/b> (POLIMI), a world-class scientific institution engaged in cutting-edge research, training and technology transfer, announced the signing of a research contract and the initiation of a project to bear on the challenging problem of identifying specific cells in complex tissues through designing, training and deployment of a deep learning model able to detect them.\n<\/p>\n

\nProf. Giacomo Boracchi of the DEIB will lead the research bringing his expertise in image processing and machine learning. In particular, the approach will aim to recognize clinically relevant cells of specific types in darkfield images of lung tissue acquired from the Ikoniscope20. Segmentation of single cell nuclei is a frequent challenge of microscopy image processing, often being the first step of many quantitative data analysis pipelines.\n<\/p>\n

\nThe ongoing collaboration will allow Ikonisys to further enhance its advanced image analysis capabilities and to accelerate the development of the Ikoniscope AI project with the implementation of deep learning models and novel state-of-art techniques into the instrument\u2019s workflow, leading to the development of new applications or enhancement of the existing ones, especially in the most challenging fields such as Circulating Tumor Cells.\n<\/p>\n

\nPlease find the full press release on the investors website<\/a>.\n<\/p>\n

\nAbout Ikonisys<\/b>\n<\/p>\n

\nIkonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20\u00ae platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIkonisys<\/b>
Alessandro Mauri
\n
CFO
\n
investors@ikonisys.com<\/a>\n<\/p>\n

\nNewCap<\/b>
Olivier Bricaud \/ Louis-Victor Delouvrier
\n
Investor Relations
\n
Ikonisys@newcap.eu<\/a>
Tel.: +33 (0)1 44 71 94 92\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PARIS–(BUSINESS WIRE)–Ikonisys SA (Code ISIN: FR00140048X2 \/ Mn\u00e9monique: ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs and the Department of Electronics, Information and Bioengineering (DEIB) of Politecnico di Milano (POLIMI), a world-class scientific institution engaged in cutting-edge research, training and technology transfer, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44291","6":"format-standard","7":"category-industry"},"yoast_head":"\nIkonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PARIS–(BUSINESS WIRE)–Ikonisys SA (Code ISIN: FR00140048X2 \/ Mn\u00e9monique: ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs and the Department of Electronics, Information and Bioengineering (DEIB) of Politecnico di Milano (POLIMI), a world-class scientific institution engaged in cutting-edge research, training and technology transfer, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-24T17:01:25+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering\",\"datePublished\":\"2022-05-24T17:01:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\\\/\"},\"wordCount\":385,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\\\/\",\"name\":\"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-05-24T17:01:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/","og_locale":"en_US","og_type":"article","og_title":"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering - Pharma Trend","og_description":"PARIS–(BUSINESS WIRE)–Ikonisys SA (Code ISIN: FR00140048X2 \/ Mn\u00e9monique: ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs and the Department of Electronics, Information and Bioengineering (DEIB) of Politecnico di Milano (POLIMI), a world-class scientific institution engaged in cutting-edge research, training and technology transfer, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-24T17:01:25+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering","datePublished":"2022-05-24T17:01:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/"},"wordCount":385,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/","url":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/","name":"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-05-24T17:01:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ikonisys-signs-contract-and-initiates-research-activities-with-politecnico-di-milano-a-world-leading-public-scientific-technological-university-in-the-field-of-computer-science-and-bioengineering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ikonisys Signs Contract and Initiates Research Activities With Politecnico Di Milano, a World Leading Public Scientific-technological University in the Field of Computer Science and Bioengineering"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44291"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44291\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}